Krsnaa Diagnostics Limited — Updates, 12-05-2025: Press Release

Krsnaa Diagnostics has announced a board meeting on the financial results for the quarter and half-year. FY25 revenue rose 16% YoY to ₹717 Cr, driven by higher patient volumes and competitive pricing. EBITDA increased 34% to ₹196 Cr with margins improving to 27%, while PAT grew 37% to ₹78 Cr (11% margin). The company is shifting to an asset-light model via partnerships to reduce capex and expanding oncology PET-CT services. Strong PPP tender wins and geographic growth in underpenetrated tier 2-3 markets support solid growth potential.